keyword
MENU ▼
Read by QxMD icon Read
search

Lymphoma FDG PET/CT

keyword
https://www.readbyqxmd.com/read/28421406/whole-body-mri-with-qualitative-and-quantitative-analysis-of-dwi-for-assessment-of-bone-marrow-involvement-in-lymphoma
#1
Annalisa Balbo-Mussetto, Chiara Saviolo, Alberto Fornari, Daniela Gottardi, Massimo Petracchini, Annalisa Macera, Chiara Valentina Lario, Teresa Gallo, Corrado Tarella, Stefano Cirillo
AIM: Our study aimed to investigate the role of qualitative and quantitative whole body MRI with DWI for assessment of bone marrow involvement (BMI) in newly diagnosed lymphoma using FDG PET-CT and bone marrow biopsy (BMB) as reference standard. MATERIALS AND METHODS: We retrospectively evaluated 56 patients with newly diagnosed lymphoma (21 Hodgkin's lymphoma and 35 non-Hodgkin's lymphoma) who underwent random unilateral BMB, FDG PET-CT and Wb-MRI-DWI for initial staging...
April 18, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/28418952/fdg-pet-ct-findings-of-nodular-sclerosis-subtype-classic-hodgkin-lymphoma-presented-as-mediastinal-nodal-lesions-at-onset-but-as-predominant-osseous-disease-at-relapse
#2
Kun Zheng, Hongming Zhuang
Nodular sclerosis-subtype classic Hodgkin lymphoma in general manifests as bulky mediastinal lymphadenopathy but very rarely involves bones. We report FDG PET/CT findings of a 19-year-old man with pathology-proven, nodular sclerosis-type classic Hodgkin lymphoma. His initial FDG PET/CT scan at the diagnosis showed only hypermetabolic lymphadenopathy in the mediastinum. However, the FDG PET/CT acquired when the disease recurred 20 months later showed predominant osseous disease without additional nodal lesions outside the mediastinum...
April 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28416502/interim-pet-driven-strategy-in-de-novo-diffuse-large-b-cell-lymphoma-do-we-trust-the-driver
#3
Steven Le Gouill, Rene-Olivier Casasnovas
FDG-PET has become central tool for both accurate initial staging and determination of prognosis after treatment of diffuse Large B Cell Lymphoma (DLBCL). However, the role of PET during treatment (iPET) in daily practice remains a matter of significant debate. This perspective reviews the published studies on iPET in DLBCL including the methods used to analyze iPET, its timing, and studies of iPET-driven therapy to illuminate where daily practice may benefit from the use of iPET. When performed after 2 and/or 4 courses of immunochemotherapy iPET has a very good negative predictive value, utilizing both visual (qualitative) and semi-quantitative methods...
April 17, 2017: Blood
https://www.readbyqxmd.com/read/28414669/a-case-of-hepatosplentic-t-cell-lymphoma-a-rare-aggressive-tumor-of-the-young
#4
S Cingam, S Patel, N Koshy
INTRODUCTION: Hepatosplenic T-cell lymphoma (HSTCL); is an unusual entity first described in 1990 that predominantly affects middle-aged men and is classified by WHO under peripheral T-cell lymphomas. We present a 26-year-old man with HSCTL treated with a non-CHOP regimen. CASE: A 26 year old immigrant from Cameroon without significant past medical history presented with abdominal discomfort that was first noted 1 month prior at which time he was elbowed in abdomen during a basketball game...
March 2017: Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society
https://www.readbyqxmd.com/read/28411336/fdg-pet-for-therapy-monitoring-in-hodgkin-and-non-hodgkin-lymphomas
#5
REVIEW
Sally F Barrington, Regine Kluge
PET using (18)F-FDG for treatment monitoring in patients with lymphoma is one of the most well-developed clinical applications. PET/CT is nowadays used during treatment to assess chemosensitivity, with response-adapted therapy given according to 'interim' PET in clinical practice to adults and children with Hodgkin lymphoma. PET is also used to assess remission from disease and to predict prognosis in the pretransplant setting. Mature data have been reported for the common subtypes of aggressive B-cell lymphomas, with more recent data also supporting the use of PET for response assessment in T-cell lymphomas...
April 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28388273/musculoskeletal-imaging-findings-of-hematologic-malignancies
#6
Shannon M Navarro, George R Matcuk, Dakshesh B Patel, Matthew Skalski, Eric A White, Anderanik Tomasian, Aaron J Schein
Hematologic malignancies comprise a set of prevalent yet clinically diverse diseases that can affect every organ system. Because blood components originate in bone marrow, it is no surprise that bone marrow is a common location for both primary and metastatic hematologic neoplasms. Findings of hematologic malignancy can be seen with most imaging modalities including radiography, computed tomography (CT), technetium 99m ((99m)Tc) methylene diphosphonate (MDP) bone scanning, fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT, and magnetic resonance (MR) imaging...
April 7, 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28385793/reply-fact-sheet-about-interim-and-end-of-treatment-18-f-fdg-pet-ct-in-lymphoma
#7
Lale Kostakoglu
No abstract text is available yet for this article.
April 6, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28382828/use-of-fdg-pet-ct-in-identification-of-bone-marrow-involvement-in-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma-comparison-with-iliac-crest-bone-marrow-biopsy
#8
Alexandra R Teagle, Hannah Barton, Elizabeth Charles-Edwards, Sabina Dizdarevic, Timothy Chevassut
Background Non-Hodgkin's lymphoma (NHL) accounts for around 4% of new cancer cases annually. Bone marrow involvement is important for staging and management. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is used increasingly to identify this, in addition to bone marrow biopsy (BMB), which is seen as "gold" reference standard. Purpose To compare determination of bone marrow involvement by FDG PET/CT against BMB in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)...
January 1, 2017: Acta Radiologica
https://www.readbyqxmd.com/read/28381690/18f-fdg-pet-ct-is-effective-in-distinguishing-myelofibrosis-due-to-bone-marrow-infiltration-of-diffuse-large-b-cell-lymphoma-from-triple-negative-primary-myelofibrosis
#9
Takuma Kumagai, Yoko Satoh, Megumi Koshiishi, Saori Ooishi, Yuki Sueki, Kei Nakajima, Toru Mitsumori, Keita Kirito
Although myelofibrosis is mainly associated with myeloproliferative neoplasms (MPN), especially primary myelofibrosis (PMF), a variety of hematological malignancies, including acute myeloid leukemia, multiple myeloma and malignant lymphoma, also cause myelofibrosis with markedly varying degrees of severity. Thus, it is extremely important to accurately diagnose the underlying diseases that cause fibrosis in bone marrow. Analyses of JAK2, MPL and calreticulin gene mutations are useful for distinguishing MPN from other diseases, since 90% of MPN patients have a mutation in one of these genes...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28379322/international-working-group-consensus-response-evaluation-criteria-in-lymphoma-recil-2017
#10
A Younes, P Hilden, B Coiffier, A Hagenbeek, G Salles, W Wilson, J F Seymour, K Kelly, J Gribben, M Pfreunschuh, F Morschhauser, H Schoder, A D Zelenetz, J Rademaker, R Advani, N Valente, C Fortpied, T E Witzig, L H Sehn, A Engert, R I Fisher, P-L Zinzani, M Federico, M Hutchings, C Bollard, M Trneny, Y A Elsayed, K Tobinai, J S Abramson, N Fowler, A Goy, M Smith, S Ansell, J Kuruvilla, M Dreyling, C Thieblemont, R F Little, I Aurer, M H J Van Oers, K Takeshita, A Gopal, S Rule, S de Vos, I Kloos, M S Kaminski, M Meignan, L H Schwartz, J P Leonard, S J Schuster, V E Seshan
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma...
April 3, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28357549/fdg-uptake-in-cervical-lymph-nodes-in-children-without-head-and-neck-cancer
#11
Reza Vali, Alaa A Bakari, Eman Marie, Mahnaz Kousha, Martin Charron, Amer Shammas
BACKGROUND: Reactive cervical lymphadenopathy is common in children and may demonstrate increased (18)F-fluoro-deoxyglucose ((18)F-FDG) uptake on positron emission tomography/computed tomography (PET/CT). OBJECTIVE: We sought to evaluate the frequency and significance of (18)F-FDG uptake by neck lymph nodes in children with no history of head and neck cancer. MATERIALS AND METHODS: The charts of 244 patients (114 female, mean age: 10.4 years) with a variety of tumors such as lymphoma and post-transplant lymphoproliferative diseases (PTLD), but no head and neck cancers, who had undergone (18)F-FDG PET/CT were reviewed retrospectively...
March 29, 2017: Pediatric Radiology
https://www.readbyqxmd.com/read/28355370/targeting-personalized-medicine-in-a-non-hodgkin-lymphoma-patient-with-18f-fdg-and-18f-choline-pet-ct
#12
Thalles H Ribeiro, Raul S, Ana Carolina G Castro, Eduardo Paulino, Marcelo Mamede
Early diagnosis and staging of non-Hodgkin lymphoma (NHL) is essential for therapeutic strategy decision. Positron emission tomography/computed tomography (PET/CT) with fluordeoxyglucose (FDG), a glucose analogue, labeled with fluor-18 (18F-FDG) has been used to evaluate staging, therapy response and prognosis in NHL patients. However, in some cases, 18F-FDG has shown false-positive uptake due to inflammatory reaction after chemo and/or radiation therapy. In this case report, we present a NHL patient evaluated with 18F-FDG and 18F-choline PET/CT scan imaging pre- and post-therapy...
February 2017: Revista da Associação Médica Brasileira
https://www.readbyqxmd.com/read/28321090/splenic-marginal-zone-lymphoma-complicated-by-cold-agglutinin-disease
#13
Kiyosumi Ochi, Kazuaki Yokoyama, Nobuhiro Ohno, Yasunori Ota, Arinobu Tojo
Splenic marginal zone lymphoma (SMZL) is a rare low-grade B-cell lymphoma accounting for less than 1% of lymphoid neoplasms and is often associated with autoimmune disorders. A 48-year-old woman presented with severe anemia due to steroid-refractory cold agglutinin disease (CAD), and was referred to our hospital for management of progressive systemic illness and high fever. On admission, she showed elevated serum soluble IL-2R and mild splenomegaly. PET/CT revealed FDG accumulation in the spleen and bone. She was pathologically diagnosed as having splenic marginal zone lymphoma by splenectomy and received 8 cycles of rituximab every 2 weeks, resulting in marked improvement of anemia...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28315904/prognostic-value-of-bone-marrow-18-f-fdg-uptake-on-pet-ct-in-lymphoma-patients-with-negative-bone-marrow-involvement
#14
Jeong Won Lee, Sang Cheol Lee, Han Jo Kim, Sang Mi Lee
OBJECTIVE: The study evaluated the significance of 18F fluorodeoxyglucose ((18)F-FDG) uptake of bone marrow (BM) for predicting progression-free survival (PFS) in lymphoma patients without BM involvement. SUBJECTS AND METHODS: Ninety-five patients with histopathologically proven lymphoma, 7 Hodgkin's lymphoma and 88 non-Hodgkin's lymphoma, who underwent (18)F-FDG positron emission tomography/computed tomography (PET/CT) and BM biopsy for staging work-up and 40 normal subjects were retrospectively enrolled...
January 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28295218/-18-f-fdg-pet-ct-in-the-staging-and-management-of-indolent-lymphoma-a-prospective-multicenter-pet-registry-study
#15
Ur Metser, Jill Dudebout, Tara Baetz, David C Hodgson, Deanna L Langer, Pamela MacCrostie, Victor Mak, Noam Tau
BACKGROUND: To measure the clinical impact of pretreatment fludeoxyglucose positron emission tomography/computed tomography (PET/CT) on the staging and management of apparent limited stage indolent lymphoma being considered for curative radiation therapy. METHODS: We conducted a prospective multicenter registry study that included 197 patients accrued between May 1, 2012, and December 31, 2015. Pre-PET/CT stage, determined by clinical and CT data, was documented...
March 13, 2017: Cancer
https://www.readbyqxmd.com/read/28291005/the-correlation-between-pre-treatment-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-parameters-and-clinical-prognostic-factors-in-pediatric-hodgkin-lymphoma
#16
Ebru Tatcı, İnci Uslu Biner, Suna Emir, Hikmet Gülşah Tanyıldız, Özlem Özmen, Engin Alagöz, Atila Gökçek, Gürses Şahin
OBJECTIVE: To compare standardized uptake values (SUV) derived from pre-treatment (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging and clinical prognostic factors in pediatric patients with Hodgkin lymphoma (HL). METHODS: Pre-treatment FDG PET/CT findings of 28 children with HL were evaluated in this retrospective study. Metabolic tumor volume (MTV), SUVmax normalized by weight (SUVweight), lean body mass (SUVlbm), body surface area (SUVbsa) and plasma glucose levels of tumors (SUVglucose) were calculated using pre-treatment FDG PET/CT scan images...
February 5, 2017: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/28291004/-18-f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-for-other-thyroid-cancers-medullary-anaplastic-lymphoma-and-so-forth
#17
Mine Araz, Derya Çayır
Positron emission tomography/computed tomography (PET/CT) with (18)F-fluorodeoxyglucose (FDG) is used in staging, restaging, and evaluation of therapy response in many cancers as well as differentiated thyroid carcinomas especially in non-iodine avid variants. Its potential in less frequent thyroid tumors like medullary, anaplastic thyroid cancers, thyroid lymphoma and metastatic tumors of the thyroid however, is not well established yet. The aim of this review is to provide an overview on the recent applications and indications of (18)F-FDG PET/CT in these tumors and to focus on the controversies in the clinical setting...
February 5, 2017: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/28290723/accuracy-of-18-f-fdg-pet-ct-to-detect-bone-marrow-clearance-in-patients-with-peripheral-t-cell-lymphoma-tissue-remains-the-issue
#18
Anthony Q Pham, Stephen M Broski, Thomas M Habermann, Dragan Jevremovic, Gregory A Wiseman, Andrew L Feldman, Matthew J Maurer, Kay M Ristow, Thomas E Witzig
Staging of peripheral T-cell non-Hodgkin lymphoma (PTCL) is determined by 18-F FDG PET scan and bone marrow biopsy. This study addressed the accuracy of PET at detecting bone marrow (BM) involvement at restaging in patients with known involvement pretreatment. We identified patients with biopsy proven BM PTCL at diagnosis and concomitant BM and PET at the end of therapy. Pre-treatment PET demonstrated 50% (8/16) had a false-negative PET scan of the BM. After induction, repeat biopsy revealed 62.5% (10/16) with BM involvement...
March 14, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28287948/spectrum-of-ct-findings-in-thoracic-extranodal-non-hodgkin-lymphoma
#19
Mathew P Bligh, Joy N Borgaonkar, Steven C Burrell, David A MacDonald, Daria Manos
Non-Hodgkin lymphoma (NHL) frequently manifests in extranodal structures in the chest, often in the form of secondary involvement but occasionally as primary disease. Because staging and treatment are affected by the presence of extranodal disease at imaging, radiologists' interpretation and management of suspicious findings are critical to patient care. Unfortunately, owing to considerable imaging overlap with other diseases, primary extranodal lymphoma is difficult to diagnose with imaging alone. Radiologists should have a heightened degree of suspicion in patients at risk (including patients with immune compromise, autoimmune diseases, or a history of stem cell or solid organ transplant) or with particular imaging appearances (including the vertebral wraparound sign, nonresolving consolidation, an infiltrative soft-tissue mass, and lesions demonstrating vascular encasement without invasion)...
March 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28270020/18f-fdg-pet-ct-and-extragastric-malt-lymphoma-role-of-ki-67-score-and-plasmacytic-differentiation
#20
Domenico Albano, Giovanni Bosio, Raffaele Giubbini, Francesco Bertagna
The detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in extragastric mucosa associated lymphoid tissue (MALT) lymphoma is under debate and the reason is not clear. Our aim was to investigate the metabolic behavior of extragastric MALT lymphoma and whether the histological features (Ki-67 index and plasmacytic differentiation, PD) might explain it. PET/CT images were analyzed visually and semi-quantitatively and compared with Ki-67 index and PD...
March 7, 2017: Leukemia & Lymphoma
keyword
keyword
84999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"